Treatment of acute lymphoblastic leukemia in Hong Kong children: HKALL 93 study

Li, C. K.; Chik, Ki Wai; Chan, Godfrey C. F.; Yuen, HL; Lee, Acw; Li, C. Keung; Shing, Matthew Ming Kong; Ha, Sy; Luk, Chung-Wing; Ling, Siu Cheung; Cheung, Albert Y.

doi:10.1002/hon.698

Cited by 20 publications

(22 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Japan [18] and Hong Kong [19] have reported incidences of 48 and 57% respectively, figures that are lower than those reported by UKALLXI2001 [20] and CCG [17] for other races. However, our results indicate that 121 (92%) patients out of a study group of 132 had chromosomal abnormalities, an incidence higher than previously reported regardless of race.…”

Section: Discussioncontrasting

confidence: 64%

Cytogenetic analysis in childhood acute lymphoblastic leukemia: experience at a single institution in Korea

et al. 2008

View full text Add to dashboard Cite

We evaluated major cytogenetic abnormalities associated with childhood acute lymphoblastic leukemia (ALL) through both fluorescent in situ hybridization and conventional chromosomal analysis for 132 ALL patients diagnosed at St Mary's Hospital in Korea. Chromosome abnormalities have been detected in 92% of patients. Eighteen (14%) patients showed numerical abnormalities only, 50 (38%) patients showed structural abnormalities only, and 53 (40%) patients showed both. The simultaneous trisomies 4, 10 and 17 were observed in 23 (17%) patients. Of the patients with abnormal karyotypes, recurrent structural abnormalities were determined in 103 (78%) cases. t(12;21)(q13;q22) was found in 29 (22%) out of 132 patients, 9p abnormalities in 13 (10%) patients, t(1;19)(q23;p13.3) in 11 (8%) patients, t(9;22)(q34;q11.2) in 11 (8%) patients, and 11q23 abnormalities in 7 (5%) patients. Interestingly, we identified five uncommon translocations such as t(5;12) (q33;p13), t(14;19)(q32;q13.1), t(12;16)(p13;q13), der(1)t(1;12)(p32;p13), and t(5;15)(p15;q11.2). Our study pool is representative of pediatric ALL patients in Korea as it consists of about 20% of patients diagnosed annually in Korea. We believe that the data provided will aid in comparative studies of the treatment outcomes, as well as the type and incidence of chromosomal abnormalities associated with childhood ALL in various Asian nations and Western countries.

show abstract

Section: Discussioncontrasting

confidence: 64%

Cytogenetic analysis in childhood acute lymphoblastic leukemia: experience at a single institution in Korea

et al. 2008

View full text Add to dashboard Cite

show abstract

“…In contrast, some authors reported that the WBC count is a significant prognostic factor. [15][16][17][18] In conclusion, compared with reports from developed countries, our data with modified ALL-BFM 95 showed a lower EFS and a higher mortality rate in CR although a satisfying remission rate and DFS. The protocols and establishment of strategies to reduce deaths from infection in CR must be our priority.…”

Section: Discussioncontrasting

confidence: 50%

Childhood Acute Lymphoblastic Leukemia in Turkey: Factors Influencing Treatment and Outcome

Hazar

Karasu²,

Uygun³

et al. 2010

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

There is limited data about the long-term treatment outcome and prognosis of childhood acute lymphoblastic leukemia (ALL) in developing countries. Our study was designed to assess survival data and identify risk factors. Data of 142 children with ALL who were treated with a modified BFM 95 protocol between 1997 and 2007 were evaluated. The median age was 4.3 years. Complete remission (CR) rate after induction phase was 93.5%; with 2.1% induction-related mortality and 0.7% having resistance disease. Of complete responders, 67.1% are in continuous CR with a median follow-up of 63 months (range: 24 to 153 mo). Treatment-related mortality was 17.7% and the total rate of treatment abandonment was 3.5%. The probability of event-free survival was 67.3% (95% confidence interval 59.3-75.3) at 4 years and 63.2% (95% confidence interval 54.4-72.0) at 8 years. This report examines children with ALL treated with a modified ALL-BFM 95 protocol in a tertiary care center in Turkey with adequate follow up and demonstrates the need for improvements especially for patients with unfavorable risk group and strategies to reduce deaths from infection in CR to keep pace with cure rates in developed countries.

show abstract

“…5 TRM commonly causes treatment failure in LICs. Whereas ALL in HICs has been associated with TRM rates of 1% to 3%, [6][7][8][9][10][11] the few studies that have investigated LICs have identified rates from 11% to 21%. 4,[12][13][14][15] In El Salvador, 12.5% of children with ALL experienced TRM.…”

mentioning

confidence: 99%

Treatment‐related mortality in children with acute lymphoblastic leukemia in Central America

Gupta

Antillón²,

Bonilla

et al. 2011

Cancer

View full text Add to dashboard Cite

BACKGROUND:The objectives of this study were to describe the incidence, timing, and predictors of treatmentrelated mortality (TRM) among children with acute lymphoblastic leukemia (ALL) in El Salvador, Guatemala, and Honduras. METHODS: Patients aged <20 years who were diagnosed with ALL between January 2000 and March 2008, who received treatment in any of the 3 countries, and who started induction chemotherapy were included in the study. Almost all patients were treated on the El Salvador-Guatemala-Honduras II protocol, which was based on the St. Jude Total XIII and XV protocols. Biologic, socioeconomic, and nutritional variables were examined as predictors of TRM. RESULTS: Of 1670 patients, TRM occurred as a first event in 156 children (9.3%); TRM occurred during remission induction therapy in 92 of 156 children (59%), between remission induction and maintenance therapy in 27 of 156 children (17%), and during maintenance therapy in 37 of 156 children (24%). Although the TRM rate decreased in patients who were diagnosed after July 1, 2004 (11.2% vs 7.9%; P ¼ .02), the rate of induction death did not change (5.2% vs 5.8%; P ¼ .58). Independent predictors of induction death included higher risk ALL (odds ratio [OR], 1.84; 95% confidence interval [CI], 1.03-3.27; P ¼ .04), lower initial platelet counts (OR per 10 Â 10

show abstract

Treatment of acute lymphoblastic leukemia in Hong Kong children: HKALL 93 study

Cited by 20 publications

References 17 publications

Cytogenetic analysis in childhood acute lymphoblastic leukemia: experience at a single institution in Korea

Cytogenetic analysis in childhood acute lymphoblastic leukemia: experience at a single institution in Korea

Childhood Acute Lymphoblastic Leukemia in Turkey: Factors Influencing Treatment and Outcome

Treatment‐related mortality in children with acute lymphoblastic leukemia in Central America

Contact Info

Product

Resources

About